FluoroPharma Medical, Inc. announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue (18) F-FCPHA at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% |
|
0.00% | 0.00% |
2022 | FluoroPharma Medical, Inc. Announces Executive Changes | CI |
2022 | FluoroPharma Medical, Inc. Appoints Frank I Igwealor as CFO | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.76K | |
+21.85% | 47.96B | |
+0.85% | 42.45B | |
+43.96% | 41.47B | |
+26.41% | 31.6B | |
+20.88% | 28.63B | |
-4.47% | 28.03B | |
+52.06% | 14.56B | |
+45.41% | 14.14B | |
+2.70% | 12.58B |
- Stock Market
- Equities
- FPMI Stock
- News FluoroPharma Medical, Inc.
- Fluoropharma Medical, Inc. Presents Data from Phase II Clinical Trial of 18F FCPHA